Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Live Attenuated Leishmania Infantum Centrin Deleted Mutant (Licen-/-) As a Novel Vaccine Candidate: A Field Study on Safety, Immunogenicity, and Efficacy Against Canine Leishmaniasis Publisher Pubmed



Zarei Z1, 2 ; Mohebali M2, 3 ; Dehghani H4 ; Khamesipour A5 ; Tavakkolafshari J6 ; Akhoundi B2 ; Abbaszadehafshar MJ2 ; Alizadeh Z2 ; Skandari SE5 ; Asl AD7 ; Razmi GR1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pathobiology, School Veterinary Medicine, Ferdowsi University of Mashhad, P.O. Box 91775-1793, Mashhad, Iran
  2. 2. Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, P.O. Box 14155-6446, Tehran, Iran
  3. 3. Center for Research of Endemic Parasites of Iran (CREPI), Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Basic Sciences, Faculty of Veterinary Medicine, Ferdowsi University of Mashhad, Mashhad, Iran
  5. 5. Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Immunogenetics and Tissue Culture Department, Immunology Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
  7. 7. Department of Parasitology and Entomology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Source: Comparative Immunology# Microbiology and Infectious Diseases Published:2023


Abstract

This study was designed to evaluate the safety, immunogenicity, and efficacy of a single dose of L. infantum (LiCen-/-) live attenuated candidate vaccine against canine leishmaniasis (CanL). Eighteen healthy domestic dogs with no anti-Leishmania antibodies and negative leishmanin skin test (LST) were randomly inoculated intravenously with either L. infantum (LiCen-/-) vaccine candidate in 10 dogs or phosphate-buffered saline (PBS) in 8 dogs. The safety, immunogenicity, and efficacy rate of L. infantum (LiCen-/-) vaccine candidate against CanL were evaluated by different criteria, including clinical manifestations, injection-site lesion, hematology and biochemistry values, anti-Leishmania antibodies using direct agglutination test (DAT), delayed-type hypersensitivity (DTH) using LST, and CD4+ and CD8+ T-cells subsets, as well as by measuring interferon (IFN-γ), interleukin (IL-23), IL-17, and IL-10 cytokines. Spleen aspiration and detection of Leishmania parasite using parasitological examinations (microscopy and culture) were performed in both vaccinated and control groups. Two months after intervention, each dog was challenged intraperitoneally (IP) with wide type (WT) L. infantum. Two-month follow-up post vaccination showed no clinical signs and serious side effects associated with the vaccination. A significant increase was found in the expression of IL-17, CD4+, and CD8+ gene transcripts in PBMCs, as well as increased levels of Th1 cytokines, and reduction of Th2 cytokine. The efficacy of the vaccine candidate was calculated to be 42.85%. While the time window for assessing the vaccine's effectiveness was too limited to draw any real conclusions but the preliminary results showed a moderate efficacy rate due to inoculation a single dose of L. infantum (LiCen-/-) vaccine candidate. Further investigations with more sample sizes and multiple doses of the vaccine candidate using natural challenges in the endemic areas of CanL are recommended. © 2023 Elsevier Ltd
Experts (# of related papers)
Other Related Docs
11. Delivery Systems for Leishmania Vaccine Development, Expert Review of Vaccines (2016)
17. Visceral Leishmaniasis in Southeastern Iran: A Narrative Review, Iranian Journal of Parasitology (2017)